SG11201701669PA - Flavivirus virus like particle - Google Patents
Flavivirus virus like particleInfo
- Publication number
- SG11201701669PA SG11201701669PA SG11201701669PA SG11201701669PA SG11201701669PA SG 11201701669P A SG11201701669P A SG 11201701669PA SG 11201701669P A SG11201701669P A SG 11201701669PA SG 11201701669P A SG11201701669P A SG 11201701669PA SG 11201701669P A SG11201701669P A SG 11201701669PA
- Authority
- SG
- Singapore
- Prior art keywords
- particle
- flavivirus virus
- flavivirus
- virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462048897P | 2014-09-11 | 2014-09-11 | |
| PCT/JP2015/004623 WO2016038895A1 (en) | 2014-09-11 | 2015-09-10 | Flavivirus virus like particle |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201701669PA true SG11201701669PA (en) | 2017-04-27 |
Family
ID=55453731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201701669PA SG11201701669PA (en) | 2014-09-11 | 2015-09-10 | Flavivirus virus like particle |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10098943B2 (en) |
| EP (1) | EP3191589A4 (en) |
| JP (1) | JP6942309B2 (en) |
| KR (1) | KR102532832B1 (en) |
| CN (1) | CN106687590B (en) |
| AR (1) | AR101814A1 (en) |
| AU (1) | AU2015313650B2 (en) |
| BR (1) | BR112017004770A8 (en) |
| CA (1) | CA2960102C (en) |
| MX (1) | MX2017003117A (en) |
| PH (1) | PH12017500450A1 (en) |
| SG (1) | SG11201701669PA (en) |
| TW (1) | TWI695842B (en) |
| WO (1) | WO2016038895A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9637532B2 (en) | 2013-07-12 | 2017-05-02 | Vlp Therapeutics, Llc | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen |
| US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
| US10799575B2 (en) * | 2015-06-25 | 2020-10-13 | Technovax, Inc. | Flavivirus and alphavirus virus-like particles (VLPS) |
| BR112020004781A2 (en) * | 2017-09-11 | 2020-09-24 | Tengen Biomedical Company | arbovirus particle, composition, insect cell and mammalian cell |
| CN113429479B (en) * | 2018-04-04 | 2023-03-10 | 中国科学院微生物研究所 | High-sensitivity yellow fever virus humanized monoclonal antibody and application thereof |
| KR101970963B1 (en) * | 2018-12-19 | 2019-04-23 | 주식회사 엠디헬스케어 | DNA aptamer binding specifically to yellow fever virus envelope protein domain III (YFV EDIII) and uses thereof |
| EP3976768A1 (en) * | 2019-05-28 | 2022-04-06 | Chiang Mai University | Mature virus-like particles of flaviviruses |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8923123D0 (en) | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
| DE69120146T2 (en) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | GENERATION OF XENOGENIC ANTIBODIES |
| WO1993010152A1 (en) | 1991-11-16 | 1993-05-27 | Smithkline Beecham Biologicals S.A. | HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG |
| US5580773A (en) | 1992-06-17 | 1996-12-03 | Korea Green Cross Corporation | Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV) |
| CA2143491C (en) | 1994-03-01 | 2011-02-22 | Yasumasa Ishida | A novel peptide related to human programmed cell death and dna encoding it |
| CA2232669A1 (en) | 1995-09-27 | 1997-04-03 | Frances Joanne Morling | Recombinant viruses incorporating a protease cleavable protein |
| JP2002507393A (en) * | 1998-02-11 | 2002-03-12 | マキシジェン， インコーポレイテッド | Antigen library immunization |
| JP2002507392A (en) * | 1998-02-11 | 2002-03-12 | マキシジェン， インコーポレイテッド | Optimization of immunomodulatory properties of gene vaccines |
| US6808710B1 (en) | 1999-08-23 | 2004-10-26 | Genetics Institute, Inc. | Downmodulating an immune response with multivalent antibodies to PD-1 |
| JP4080423B2 (en) | 2001-05-30 | 2008-04-23 | トランジェーヌ、ソシエテ、アノニム | Adenovirus protein IX and its domains involved in capsid assembly, transcriptional activity and nuclear reorganization |
| CA2481479C (en) * | 2002-02-26 | 2012-12-11 | Maxygen, Inc. | Novel flavivirus antigens |
| WO2003102133A2 (en) * | 2002-05-13 | 2003-12-11 | The Regents Of The University Of California | Chemical modifications to polymer surfaces and the application of polymer grafting to biomaterials |
| FI2206517T3 (en) | 2002-07-03 | 2023-10-19 | Ono Pharmaceutical Co | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
| EP1583500A4 (en) | 2002-11-13 | 2008-02-13 | Us Navy | Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines |
| MXPA05012754A (en) | 2003-05-29 | 2006-05-17 | Army Medical Res Inst For I | Live attenuated viral vaccines for eastern equine encephalitis virus. |
| JP4506301B2 (en) | 2003-09-30 | 2010-07-21 | ブラザー工業株式会社 | Ink cartridge and inkjet printer |
| CA2547511A1 (en) | 2003-12-01 | 2005-07-28 | Dow Global Technolgies Inc. | Recombinant icosahedral virus like particle production in pseudomonads |
| MXPA06013124A (en) | 2004-05-18 | 2007-05-23 | Alphavax Inc | Tc-83-derived alphavirus vectors, particles and methods. |
| AU2007200847B2 (en) * | 2004-07-27 | 2010-06-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION | Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use |
| KR20070104881A (en) | 2004-10-14 | 2007-10-29 | 크루셀 홀란드 비.브이. | Malaria prime/boost vaccines |
| WO2006088229A1 (en) | 2005-02-16 | 2006-08-24 | The Circle For The Promotion Of Science And Engineering | Modified virus capsid protein and the use thereof |
| RU2596491C2 (en) | 2005-06-08 | 2016-09-10 | Дана-Фарбер Кэнсер Инститьют | Methods and compositions for treating persistent infections |
| GB0513421D0 (en) | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
| CU23586A1 (en) | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | METHODS AND PROTEINS FOR THE PROPHLACTIC AND / OR THERAPEUTIC TREATMENT OF THE FOUR SEROTYPES OF THE DENGUE VIRUS AND OTHER FLAVIVIRUS |
| US8216996B2 (en) | 2006-03-03 | 2012-07-10 | Ono Pharmaceutical Co., Ltd. | Multimer of extracellular domain of cell surface functional molecule |
| WO2008025067A1 (en) | 2006-08-30 | 2008-03-06 | Hepgenics Pty Ltd | Recombinant proteins and virus like particles comprising l and s polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same |
| WO2009079185A2 (en) | 2007-11-26 | 2009-06-25 | Novartis Vaccines And Diagnostics, Inc. | Methods of generating alphavirus particles |
| WO2010062396A2 (en) | 2008-11-26 | 2010-06-03 | Government Of The United States Of America , As Represented By The Secretary, Department Of Health And Human Services | Virus like particle compositions and methods of use |
| ES2752323T3 (en) | 2009-09-18 | 2020-04-06 | Fraunhofer Usa Inc | Virus-like particles comprising target proteins fused to plant virus coat proteins |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2012006180A1 (en) | 2010-06-29 | 2012-01-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv immunogens |
| CN101948850A (en) * | 2010-08-13 | 2011-01-19 | 中国疾病预防控制中心病毒病预防控制所 | Preparation method and application of virus-like particles of dengue viruses |
| WO2012023995A1 (en) | 2010-08-18 | 2012-02-23 | Takayuki Shiratsuchi | Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes |
| WO2012106356A2 (en) | 2011-01-31 | 2012-08-09 | GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES | Virus-like particles and methods of use |
| CN103561771B (en) | 2011-03-17 | 2019-01-04 | 伯明翰大学 | The immunization therapy redirected |
| SG10201607787RA (en) | 2011-06-17 | 2016-11-29 | Bharat Biotech Int Ltd | Vaccine Composition Comprising An Inactivated Chikungunya Virus Strain |
| CA2836501A1 (en) | 2011-07-12 | 2013-01-17 | Gwong-Jen J. Chang | Identification of a west nile virus cd4 t cell epitope and use thereof |
| CN102321639B (en) | 2011-09-08 | 2013-06-26 | 中国疾病预防控制中心病毒病预防控制所 | Preparation method of virus-like particles (VLPs) of Chikungunya virus (CHIKV) and its application |
| EP2771366A4 (en) | 2011-10-25 | 2015-06-03 | Florida Gulf Coast University Board Of Trustees | Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes |
| AR092796A1 (en) | 2012-02-16 | 2015-05-06 | Vlp Therapeutics Llc | VIRAL TYPE PARTICULATED COMPOSITION |
| US9821050B2 (en) * | 2012-04-02 | 2017-11-21 | The University Of North Carolina At Chapel Hill | Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions |
| AU2013262691B2 (en) | 2012-05-16 | 2018-12-20 | Immune Design Corp. | Vaccines for HSV-2 |
| WO2014016362A1 (en) * | 2012-07-24 | 2014-01-30 | Sanofi Pasteur | Vaccine compositions for prevention against dengue virus infection |
| AU2014275772B2 (en) | 2013-06-03 | 2020-01-02 | Vlp Therapeutics, Inc. | Malaria vaccine |
| US9637532B2 (en) | 2013-07-12 | 2017-05-02 | Vlp Therapeutics, Llc | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen |
| US10060924B2 (en) | 2014-03-18 | 2018-08-28 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Distinguishing flavivirus infection using a recombinant mutant envelope protein |
| CN106795513B (en) | 2014-08-08 | 2021-06-11 | Vlp治疗公司 | Virus-like particles comprising a modified envelope protein E3 |
| US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
| US9363353B1 (en) | 2014-12-04 | 2016-06-07 | Hon Man Ashley Chik | Mobile phone docks with multiple circulating phone connectors |
| BR112017014219A2 (en) | 2014-12-31 | 2018-03-06 | The Usa As Represented By The Secretary Dept Of Health And Human Services | multivalent nanoparticle-based vaccines |
| CN107849558A (en) | 2015-06-12 | 2018-03-27 | 国立大学法人三重大学 | Human Parainfluenza virus type 2 carrier and vaccine |
| US10799575B2 (en) | 2015-06-25 | 2020-10-13 | Technovax, Inc. | Flavivirus and alphavirus virus-like particles (VLPS) |
| CA3209607A1 (en) | 2015-07-16 | 2017-01-19 | Bharat Biotech International Limited | Vaccine compositions |
| ES2937963T3 (en) | 2015-07-21 | 2023-04-03 | Modernatx Inc | Infectious disease vaccines |
| CN106085974B (en) | 2016-06-07 | 2019-08-09 | 博奥生物集团有限公司 | A kind of zika virus pseudovirion and preparation method thereof |
-
2015
- 2015-09-10 SG SG11201701669PA patent/SG11201701669PA/en unknown
- 2015-09-10 KR KR1020177009567A patent/KR102532832B1/en active IP Right Grant
- 2015-09-10 CN CN201580048888.9A patent/CN106687590B/en active Active
- 2015-09-10 EP EP15840429.3A patent/EP3191589A4/en active Pending
- 2015-09-10 JP JP2017513835A patent/JP6942309B2/en active Active
- 2015-09-10 US US14/850,399 patent/US10098943B2/en active Active
- 2015-09-10 AU AU2015313650A patent/AU2015313650B2/en active Active
- 2015-09-10 CA CA2960102A patent/CA2960102C/en active Active
- 2015-09-10 MX MX2017003117A patent/MX2017003117A/en unknown
- 2015-09-10 BR BR112017004770A patent/BR112017004770A8/en active IP Right Grant
- 2015-09-10 WO PCT/JP2015/004623 patent/WO2016038895A1/en active Application Filing
- 2015-09-11 AR ARP150102897A patent/AR101814A1/en unknown
- 2015-09-11 TW TW104130067A patent/TWI695842B/en active
-
2017
- 2017-03-09 PH PH12017500450A patent/PH12017500450A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2960102C (en) | 2023-10-24 |
| US20160074501A1 (en) | 2016-03-17 |
| AU2015313650A1 (en) | 2017-04-13 |
| TWI695842B (en) | 2020-06-11 |
| CA2960102A1 (en) | 2016-03-17 |
| JP2017528139A (en) | 2017-09-28 |
| TW201612190A (en) | 2016-04-01 |
| KR102532832B1 (en) | 2023-05-16 |
| EP3191589A4 (en) | 2018-05-09 |
| US10098943B2 (en) | 2018-10-16 |
| BR112017004770A2 (en) | 2017-12-12 |
| JP6942309B2 (en) | 2021-09-29 |
| MX2017003117A (en) | 2017-06-14 |
| AR101814A1 (en) | 2017-01-11 |
| BR112017004770A8 (en) | 2023-04-11 |
| PH12017500450A1 (en) | 2017-07-31 |
| KR20170055513A (en) | 2017-05-19 |
| AU2015313650B2 (en) | 2021-07-08 |
| CN106687590A (en) | 2017-05-17 |
| EP3191589A1 (en) | 2017-07-19 |
| CN106687590B (en) | 2021-08-03 |
| WO2016038895A1 (en) | 2016-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1257480A1 (en) | Engineered virus | |
| HK1255670A1 (en) | Modified virus-like particles of cmv | |
| GB2535253B (en) | Compositions and methods | |
| IL252216A0 (en) | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | |
| HK1231471A1 (en) | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof 6-- 6--2- | |
| GB201405614D0 (en) | Particles | |
| GB201405834D0 (en) | Oncolytic virus | |
| SG11201700968PA (en) | Formulation comprising particles | |
| GB201406608D0 (en) | Virus | |
| PL3152226T3 (en) | Modified cyclopentapeptides and uses thereof | |
| GB201506381D0 (en) | Embolization particle | |
| SG11201701669PA (en) | Flavivirus virus like particle | |
| GB201412841D0 (en) | Particles | |
| GB2540240B (en) | Catalyst particle | |
| GB201411526D0 (en) | Powder | |
| HK1253030A1 (en) | Piv5-based amplifying virus-like particles | |
| GB201419572D0 (en) | Virus | |
| GB2577405B (en) | Particle | |
| SG11201609908VA (en) | Virus reduction method | |
| ZA201708393B (en) | Large particles | |
| GB201402915D0 (en) | Compositions and methods | |
| GB201708709D0 (en) | Virus like particle | |
| GB201600380D0 (en) | Modified virus | |
| GB201522013D0 (en) | Virus | |
| GB201516936D0 (en) | Virus |